Efficacy of Topical Tapinarof Versus Betamethasone in the Treatment of Plaque Psoriasis

Inclusion Criteria: * Age 18 years-65 years * Clinically diagnosed plaque psoriasis involving body surface area ( BSA) of 2-20% (mild to moderate severity) * Disease duration of at least 6 months * Willing and able to provide written informed consent * Not currently using any other topical and systematic psoriasis therapy, or willing to undergo a washout period (2 weeks for topical therapies) Exclusion Criteria: * Severe psoriasis (BSA \>20% or requiring systemic therapy) * Pregnant and lactating mothers * Known hypersensitivity to Tapinarof or any of its excipients * Concurrent dermatological conditions that may interfere with assessment e.g fungal infections,atopic dermatitis * Use of systemic immunosuppressants (methotrexate, cyclosporine, biologics ) or phototherapy within 4 weeks before enrollment * History of malignancy or current active infection * Known hypersensitivity to betamethasone or Tapinarof * Use of powerful topical corticosteroids within two weeks previously